Cynthia Smith - Net Worth and Insider Trading

Cynthia Smith Net Worth

The estimated net worth of Cynthia Smith is at least $41,616 dollars as of 2024-05-26. Cynthia Smith is the Director of Akebia Therapeutics Inc and owns about 37,833 shares of Akebia Therapeutics Inc (AKBA) stock worth over $41,616. Details can be seen in Cynthia Smith's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Cynthia Smith has not made any transactions after 2020-06-08 and currently still holds the listed stock(s).

Transaction Summary of Cynthia Smith

To

Cynthia Smith Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Cynthia Smith owns 7 companies in total, including Dicerna Pharmaceuticals Inc (DRNA) , Akebia Therapeutics Inc (AKBA) , and Spero Therapeutics Inc (SPRO) among others .

Click here to see the complete history of Cynthia Smith’s form 4 insider trades.

Insider Ownership Summary of Cynthia Smith

Ticker Comapny Transaction Date Type of Owner
DRNA Dicerna Pharmaceuticals Inc 2020-06-15 director
AKBA Akebia Therapeutics Inc 2020-06-08 director
SPRO Spero Therapeutics Inc 2019-03-19 director
2016-11-01 director
2015-12-17 Chief Commercial Officer
2021-01-29 director
2022-08-11 director

Cynthia Smith Latest Holdings Summary

Cynthia Smith currently owns a total of 1 stock. Cynthia Smith owns 37,833 shares of Akebia Therapeutics Inc (AKBA) as of June 8, 2020, with a value of $41,616.

Latest Holdings of Cynthia Smith

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AKBA Akebia Therapeutics Inc 2020-06-08 37,833 1.10 41,616

Holding Weightings of Cynthia Smith


Cynthia Smith Form 4 Trading Tracker

According to the SEC Form 4 filings, Cynthia Smith has made a total of 2 transactions in Akebia Therapeutics Inc (AKBA) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Akebia Therapeutics Inc is the sale of 4,567 shares on June 8, 2020, which brought Cynthia Smith around $55,261.

Insider Trading History of Cynthia Smith

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Cynthia Smith Trading Performance

GuruFocus tracks the stock performance after each of Cynthia Smith's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Cynthia Smith is 206.59%. GuruFocus also compares Cynthia Smith's trading performance to market benchmark return within the same time period. The performance of stocks bought by Cynthia Smith within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Cynthia Smith's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Cynthia Smith

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 85.03
Relative Return to S&P 500(%) 81.4

Cynthia Smith Ownership Network

Ownership Network List of Cynthia Smith

No Data

Ownership Network Relation of Cynthia Smith


Cynthia Smith Owned Company Details

What does Dicerna Pharmaceuticals Inc do?

Who are the key executives at Dicerna Pharmaceuticals Inc?

Cynthia Smith is the director of Dicerna Pharmaceuticals Inc. Other key executives at Dicerna Pharmaceuticals Inc include See Remarks Bob D Brown , EVP & Chief Medical Officer Shreeram Aradhye , and director & President and CEO Douglas Fambrough .

Dicerna Pharmaceuticals Inc (DRNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dicerna Pharmaceuticals Inc (DRNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dicerna Pharmaceuticals Inc (DRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dicerna Pharmaceuticals Inc (DRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Dicerna Pharmaceuticals Inc Insider Transactions

No Available Data

Cynthia Smith Mailing Address

Above is the net worth, insider trading, and ownership report for Cynthia Smith. You might contact Cynthia Smith via mailing address: 508 Wrangler Drive, Suite 100, Coppell Tx 75019.

Discussions on Cynthia Smith

No discussions yet.